Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of clifutinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD-mutated acute myeloid leukemia
CTR20222667Phase 3Active
- Sponsor
- HEC Pharm
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clifutinib in acute myeloid leukemia (AML) (2 arms), sponsored by HEC Pharm. Primary endpoints: Overall survival and Complete remission or complete remission with partial hematologic recovery rate confirmed by central laboratory. Started Mar 2023; status: active.
02
Drugs
clifutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20222667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222667.